Nuvaira, a developer of novel therapeutic medical devices to treat obstructive lung diseases, announced today it has closed a $79 million equity financing led by U.S. Venture Partners, with Endeavour Vision, Qiming Venture Partners, Lightstone Ventures and Richard King Mellon Foundation joining the round, along with all of Nuvaira's existing investors: Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, Versant Ventures, Vertex Venture Holdings, and Windham Venture Partners.
Relievant Medsystems today announced that a pre‐specified interim analysis of the Level I INTRACEPT Randomized Controlled Trial (RCT) found a highly significant reduction in the Oswestry Disability Index (ODI) score in patients treated with the Intracept Procedure over patients in the non‐surgical management arm.
Relievant Medsystems today announced that the Centers for Medicare & Medicaid Services (CMS) has established Healthcare Common Procedure Coding System (HCPCS) codes C9752 and C9753 for the Intracept Procedure effective January 1, 2019
Redwood City, CA – January 3, 2019 - Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75 million equity financing.
Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics, and Amgen (NASDAQ:AMGN) today announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB).
Located in Basel, Switzerland, Medartis develops, manufactures and distributes medical internal fixation devices and surgical instruments offered in system solutions for small bone fractures focusing on the extremities.
Redwood City, CA – August 22, 2018 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration...